Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity (NASDAQ:INSM)
· seekingalpha.com
Insmed is rated Strong Buy with a $175 target, offering ~39% upside from current levels.
I have a strong interest in fundamental equity research, with a focus on companies with smaller market capitalizations. I look for underfollowed or misunderstoo...